微球栓塞支气管动脉与全身化疗治疗晚期非小细胞肺癌的临床研究

目的观察应用微球栓塞支气管动脉并灌注化疗对比全身化学药物治疗晚期非小细胞肺癌的疗效及安全性分析。方法收集2015年8月~2018年9月收治的非小细胞肺癌65例(灌注化疗栓塞组),应用微导管经支气管动脉行超选择灌注化疗栓塞,2月后复查,个别病例必要时多次灌注栓塞治疗;同时选取我院非小细胞肺癌患者57例(化学药物治疗组),化学药物治疗4~6个周期,与灌注化疗栓塞组一样2月后复查。结果栓塞组ORR 78.5%(51/65),化学药物治疗组ORR 58.3%(33/57);栓塞组患者1年生存率69.2%(45/65);化学药物治疗组患者1年生存率45.6%(26/57),两组ORR、1年生存率比较均具有统计学意义(P<0.05);严重不良反应主要为骨髓抑制(III、IV级),呕吐(III、IV)等,化疗栓塞组发生率23.1%(15/65),化学药物治疗组发生率35.1%(20/65)。结论对于难以耐受全身化学药物治疗或不愿行化学药物治疗的晚期非小细胞肺癌患者,行支气管动脉灌注化疗栓塞术,副作用小,可明显延长患者生存期。

Clinical study of bronchial arterial chemoembolization with microsphere versus systemic chemotherapy in advanced non-small cell lung cancer

Objective To observe the efficacy and safety of microsphere embolization of bronchial artery compared with systemic chemotherapy in the treatment of advanced non-small cell lung cancer.Methods A total of 65 patients with non-small cell lung cancer admitted to the Department of Interventional Oncology,Affiliated Hospital of Weifang Medical College from August 2015 to September 2018(infusion chemotherapy and embolization group)were enrolled in this study.Aftor re-examination,individual cases were treated with multiple perfusion embolization when necessary.At the same time,57 patients with non-small cell lung cancer in the oncology department(chemotherapy group)were selected.The chemotherapy was performed for 4~6 cycles,and the same as the perfusion embolization group.Results The ORR was 78.5%(51/65)in the embolization group and 58.3%(33/57)in the chemotherapy group.The one-year survival rate was 69.2%(45/65)in the embolization group and 45.6%in the chemotherapy group.(26/57),the ORR and 1-year survival rates of the two groups were statistically significant(P<0.05);the serious adverse reactions were mainly myelosuppression(III,IV),vomiting(III,IV),etc.The rate was 23.1%(15/65),and the incidence rate of chemotherapy group was 35.1%(20/65).Conclusion For patients with advanced non-small cell lung cancer who are difficult to tolerate systemic chemotherapy or who are unwilling to undergo chemotherapy,bronchial arterial chemoembolization is performed,and side effects are tolerated,which significantly prolongs the survival of patients.